We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.25 | 17.50 | 19.00 | 18.25 | 18.25 | 18.25 | 2,897 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.43 | 16.64M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/10/2019 15:20 | Yes but as we have ready today already, some will be pinching pennies and losing pounds later. lol | slartybartfaster | |
14/10/2019 14:56 | Those with the balls to buy in the 40s are being richly rewarded. The 5k at 60.35 is a little sale by me where in my customary fashion I am taking a little trading profit. However the other 175k are going nowhere! | nobbygnome | |
14/10/2019 14:42 | OPTIBIOTIX HEALTH PLC Life Sciences 14 October 2019 13:06 BST FLASH NOTE OptiBiotix Health Plc (OPTI-GB) OUTPERFORM LP-LDL achieves two major milestones Target Price 97.00p Current Price 54.00p KEY TAKEAWAY Last week, OPTI announced two major milestones for marketed ingredient LP-LDL, currently sold as a probiotic in foods and food supplements for the reduction of cholesterol: (1) achievement of process validation under good manufacturing practices ("GMP"), a necessary step in developing LP-LDL as a pharmaceutical drug; (2) confirmation of generally regarded as safe ("GRAS") status by the FDA. Both milestones reflect OPTI's commitment to improving the quality of the science and manufacturing conditions for probiotics to bring them closer to pharmaceutical standards. They should increase LP-LDL's attractiveness to both food companies looking to differentiate their products with evidence-backed ingredients and pharma companies looking to target the microbiome with live bacteria. With both events taking OPTI closer to achieving our forecasts and hence valuation expectations, we reiterate our OUTPERFORM recommendation and target price of GBp97 per share. | jestercat2 | |
14/10/2019 14:37 | Whitegold, my gran could beat Manchester United these days. The days when teams ran off the pitch elated like they won the PL after beating MU is over....for now. | elrico | |
14/10/2019 14:35 | Free version A new flash note out today by Goetz has been loaded onto the lemming google groups forum. | elrico |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions